DeepMed Research

Estetra

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

Phase 2

Active, not recruiting

Conditions: Sexual Dysfunction, Physiological

Interventions: Drug: 20 mg estetrol monohydrate
Other: Placebo

First Posted Date: 2024-03-13

Last Posted Date: 2025-01-15

Lead Sponsor: Estetra

Target Recruit Count: 82

Registration Number: NCT06308614

Locations: 🇺🇸
Estetra Study Site, Seattle, Washington, United States

Effect of Estetrol Monohydrate (E4) on QTc Interval

Phase 1

Completed

Conditions: Prolonged QTc Interval

Interventions: Drug: Estetrol 20 mg
Drug: Estetrol 100 mg
Drug: Placebo
Drug: Moxifloxacin 400 mg

First Posted Date: 2021-03-29

Last Posted Date: 2023-09-15

Lead Sponsor: Estetra

Target Recruit Count: 32

Registration Number: NCT04819906

Locations: 🇺🇸
QPS Miami, Miami, Florida, United States

Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents

Phase 3

Completed

Conditions: Safety

Interventions: Drug: E4/DRSP 15/3 mg combined tablet

First Posted Date: 2021-03-11

Last Posted Date: 2023-12-22

Lead Sponsor: Estetra

Target Recruit Count: 145

Registration Number: NCT04792385

Locations: 🇪🇪
KVL Medical Office/KVL Arstikabinet, Parnu, Estonia
🇪🇪
Sexual Health Clinic, Tallinn, Tallinn, Estonia
🇪🇪
Sexual Health Clinic, Tartu, Tartu, Estonia

and more 10 locations

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Phase 3

Completed

Conditions: Vasomotor Symptoms
Menopausal Symptoms

Interventions: Drug: Estetrol
Drug: Placebo
Drug: Progesterone

First Posted Date: 2019-12-24

Last Posted Date: 2025-01-29

Lead Sponsor: Estetra

Target Recruit Count: 1570

Registration Number: NCT04209543

Locations: 🇬🇧
Estetra Study Site, Orpington, United Kingdom
🇺🇸
Noble Clinical Research, Tucson, Arizona, United States
🇺🇸
Infinite Clinical Trials, Morrow, Georgia, United States

and more 180 locations

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women

Phase 3

Completed

Conditions: Vasomotor Symptoms
Menopausal Symptoms

Interventions: Drug: Placebo oral tablet
Drug: Estetrol oral tablet

First Posted Date: 2019-09-16

Last Posted Date: 2023-07-03

Lead Sponsor: Estetra

Target Recruit Count: 1015

Registration Number: NCT04090957

Locations: 🇨🇦
Estetra Study Site, Waterloo, Canada

Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study

Phase 1

Completed

Conditions: Contraception

Interventions: Drug: E4/DRSP
Drug: VAL

First Posted Date: 2018-05-01

Last Posted Date: 2018-12-14

Lead Sponsor: Estetra

Target Recruit Count: 24

Registration Number: NCT03512860

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

E4/DRSP Ovarian Function Inhibition Study

Phase 2

Completed

Conditions: Prevention of Pregnancy

Interventions: Drug: 15 mg E4/3 mg DRSP
Drug: 20 mcg EE/3 mg DRSP

First Posted Date: 2017-03-27

Last Posted Date: 2023-05-03

Lead Sponsor: Estetra

Target Recruit Count: 82

Registration Number: NCT03091595

Locations: 🇳🇱
Dinox BV, Groningen, Netherlands

Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers

Phase 1

Completed

Conditions: Contraception
Menopause

Interventions: Drug: 45 mg E4 single-dose
Drug: 5 mg E4 single-dose
Drug: 15 mg E4 single-dose
Drug: 15 mg E4 multiple-dose

First Posted Date: 2017-03-09

Last Posted Date: 2017-09-08

Lead Sponsor: Estetra

Target Recruit Count: 31

Registration Number: NCT03075956

Locations: 🇧🇬
COMAC, Sofia, Bulgaria

"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"

Phase 1

Completed

Conditions: Liver Metabolism
Contraception
Hemostasis Parameter

Interventions: Drug: 15 mg E4/3 mg DRSP
Drug: 30 mcg EE/150 mcg LNG
Drug: 20 mcg EE/3 mg DRSP

First Posted Date: 2016-11-08

Last Posted Date: 2018-02-05

Lead Sponsor: Estetra

Target Recruit Count: 101

Registration Number: NCT02957630

Locations: 🇳🇱
Dinox BV, Groningen, Netherlands

E4/DRSP Single and Multiple Dose PK and Early QT Study

Phase 1

Completed

Conditions: Contraception

Interventions: Drug: 75 mg E4/15 mg DRSP
Drug: Visually matching placebo
Drug: 15 mg E4/3 mg DRSP
Drug: 30 mg E4/6 mg DRSP
Drug: 60 mg E4/12 mg DRSP

First Posted Date: 2016-08-22

Last Posted Date: 2017-04-21

Lead Sponsor: Estetra

Target Recruit Count: 55

Registration Number: NCT02874248

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy